Clinical trials: in Finland
Pregnancy, Postpartum
Usability Study of Gestational and Postpartum Weight Management Program
The principal aim of this study is to evaluate the usability of the Hope-D gestational and 6 months postpartum weight management program.
- Conditions
- Pregnancy, Postpartum, Obese Pregnant Women, Weight Management
- Trial name
- Hope-D_Use (NCT07272824)
- Where
- Finland
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Turku University Hospital
Labor, Induced, Labor, Obstetric
Maternal Informing on Labor Induction: Impact on Childbirth Experience
The aim of this study is to explore the information provided to mothers about labor induction and its connection to their childbirth experience.
- Conditions
- Labor, Induced, Labor, Obstetric, Pregnancy, Humans
- Trial name
- NCT07272785
- Where
- Finland
- Volunteers
- 50 people
- Sponsor
- Turku University Hospital
Diffuse Large B-Cell Lymphoma
A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
This study is a multicenter, open-label study of polatuzumab vedotin administered by intravenous (IV) infusion in combination with rituximab, gemcitabine and oxaliplatin (R-GemOx) in participants with relapsed or refractory…
- Trial name
- POLARGO (NCT04182204)
- Testing
- Polatuzumab Vedotin, Rituximab, Gemcitabine
- Where
- 62 sites in United States, Brazil and 14 more
- Volunteers
- 270 people
- Sponsor
- Hoffmann-La Roche
Ovarian Cancer
EWOC-1 Trial: Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer
The current standard of first-line chemotherapy in advanced ovarian cancer is the combination of carboplatin AUC 5mg/mL/min and paclitaxel 175 mg.m-².
- Trial name
- EWOC-1 (NCT02001272)
- Testing
- Paclitaxel + Carboplatin every 3 weeks, Carboplatin monotherapy every 3 weeks, Weekly Paclitaxel and Carboplatin
- Where
- 63 sites in Canada, Denmark and 4 more
- Volunteers
- 120 people
- Sponsor
- Hospices Civils de Lyon
Migraine
A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in Participants 6 to 17 Years of Age
The primary objective of the study is to evaluate the effectiveness of fremanezumab as compared to placebo for the preventive treatment of chronic migraine (CM).
- Trial name
- NCT04464707
- Testing
- Fremanezumab
- Where
- 89 sites in United States, Canada and 7 more
- Volunteers
- 292 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Education, Nursing Students, Clinical Competence
Comparing Mixed Reality, Video-Based, and Instructor-Led Training for Nasogastric Tube Insertion in Nursing Students
This study explores how nursing students learn to insert a nasogastric tube (NGT), a common but potentially risky clinical procedure.
- Conditions
- Education, Nursing Students, Clinical Competence, Teaching Innovation, Nasogasrtic Tube Insertion
- Trial name
- NURSE-TRAIN (NCT07293663)
- Testing
- Mixed Reality NGT Training, Video-Based NGT Training, Instructor-Led NGT Training
- Where
- Finland
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- University of Turku
Stroke, Parkinson Disease
Videofluoroscopic Swallowing Study (VFSS)
The study procedure of simultaneous VFSS and DDS measurement will be completed in one day and the subject will be followed within 2 business days after the study procedure to monitor for adverse events.
- Conditions
- Stroke, Parkinson Disease, Multiple Sclerosis, Oropharyngeal Dysphagia
- Trial name
- PORSCHE (NCT03387267)
- Testing
- Dysphagia Detection System
- Where
- 13 sites in United States, Finland
- Volunteers
- 452 people
- Sponsor
- Société des Produits Nestlé (SPN)
Celiac Disease, Coeliac Disease
A Study of Efficacy, Safety, and Tolerability of KAN-101 in People With Celiac Disease
The study goal is to evaluate the efficacy, safety, and tolerability of KAN-101 in participants with Celiac Disease (CeD)
- Trial name
- SynCeD (NCT06001177)
- Testing
- KAN-101
- Where
- 28 sites in United States, Canada and 6 more
- Volunteers
- 55 people
- Sponsor
- Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA
Congestive Heart Failure
SyncAV Post-Market Trial
The SyncAV Post-Market Trial is a prospective, randomized, multi-center trial performed to determine if cardiac resynchronization therapy (CRT) devices programmed with SyncAV ON improve long-term CRT response compared to devices…
- Trial name
- SyncAV (NCT04100148)
- Testing
- SyncAV programmed ON, Fixed AV delay
- Where
- 104 sites in United States, Austria and 23 more
- Volunteers
- 1,686 people
- Sponsor
- Abbott Medical Devices
Prostate Hyperplasia
HappyOrNot® Smileys and the Visual Analogue Scale (VAS) in the Assessment of Urinary Symptoms
INTRODUCTION A simple and repeatable test would be valuable for assessing the severity and impact of urinary symptoms. Visual Analogue Scale (VAS) is a 10 cm line where a participant put a mark in place that describes best his…
- Trial name
- NCT07269652
- Testing
- Visual analogue scale and HappyorNot smileys
- Where
- Finland
- Volunteers
- 100 people
- Sponsor
- Seinajoki Central Hospital
Amyotrophic Lateral Sclerosis
A Study of VRG50635 in Participants With Amyotrophic Lateral Sclerosis (ALS)
The primary purpose of this study is to evaluate the safety and tolerability of VRG50635 in participants with ALS.
- Trial name
- NCT06215755
- Testing
- VRG50635
- Where
- 7 sites in Belgium, Canada and 2 more
- Volunteers
- 54 people
- Sponsor
- Verge Genomics
Cytomegalovirus Infection
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
The main purpose of this study is to evaluate the efficacy of mRNA 1647 vaccine in CMV-seronegative female participants and to evaluate the safety and reactogenicity of mRNA-1647 vaccine in all participants.
- Trial name
- NCT05085366
- Testing
- mRNA-1647
- Where
- 296 sites in United States, Australia and 11 more
- Volunteers
- 7,454 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Herpes Zoster, Herpes Zoster Vaccine
A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults
The purpose of this study was a long-term follow-up of the two studies 110390 and 113077 (ZOSTER-006/022) to assess the efficacy, safety, and immunogenicity persistence of GSK Biologicals' Herpes Zoster subunit (HZ/su) vaccine…
- Trial name
- NCT02723773
- Testing
- Herpes Zoster Vaccine GSK1437173A
- Where
- 161 sites in United States, Australia and 16 more
- Volunteers
- 7,539 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Non-small Cell Lung Cancer
A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer
This is a Phase II, randomized, multi-center, multinational, open-label, cross-over study in adult participants with PD-L1-positive NSCLC.
- Trial name
- NCT05171777
- Testing
- Atezolizumab
- Where
- 36 sites in United States, Argentina and 10 more
- Volunteers
- 179 people
- Sponsor
- Hoffmann-La Roche
Clavicle Fracture
The Scandinavian Displaced Lateral Clavicle Trial
A multicentre multinational RCT to investigate whether non-surgical treatment is non-inferior to surgical treatment for displaced extraarticular lateral clavicle fractures in adults.
- Trial name
- ScanDiLaC (NCT06981065)
- Testing
- Simple Sling and Physiotherapy, Surgical treatment
- Where
- 11 sites in Denmark, Finland and 2 more
- Volunteers
- 96 people
- Sponsor
- Uppsala University
Persistent Physical Symptoms (PPS), Functional Disorder
The Pilot of the Turku Outpatient Clinic for Functional and Fatigue Disorders
This study examined 125 working-age patients from the Turku Outpatient Clinic for Functional and Fatigue Disorders. "Patients participate in the clinic's biopsychosocial, multidisciplinary, and individually tailored…
- Conditions
- Persistent Physical Symptoms (PPS), Functional Disorder, Fatigue Syndrome, Chronic
- Trial name
- TOCliFFD (NCT07272148)
- Testing
- Biopsychosocial, multidisciplinary, and individually tailored rehabilitation for patients with persisten symptoms
- Where
- Finland
- Volunteers
- 125 people
- Sponsor
- Turku University Hospital
Colon Cancer
Colon Cancer Diagnosis With FAPI-PET Imaging
Whole body CT is the primary imaging method in staging and follow-up of colon cancer. Conventional PET-CT with 18F-labeled fluorodeoxyglucose (18F-FDG) has its limitations and has a secondary role in colon cancer protocols.
- Trial name
- NCT07272772
- Testing
- PET/CT ([F-18]FAPI-74)
- Where
- Finland
- Volunteers
- 100 people
- Sponsor
- Turku University Hospital
COVID19, Sars-Cov-2
The Safety and Antibody Response of the Nasal COV2 Vaccine Against the SARS-CoV-2 Virus
COV2 is a nasal, investigational vaccine against COVID-19, based on a serotype 5 adenoviral vector producing the SARS-CoV-2 spike protein.
- Trial name
- COV2NOSE (NCT06851611)
- Testing
- COVID-19 vaccine, low dose level, COVID-19 vaccine, high dose level, Nasal Drops
- Where
- Finland
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Rokote Laboratories Finland Oy
Metastatic Hormone-sensitive Prostate Cancer
Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer
The purpose of the study is to assess the efficacy and safety of BAY1841788 (darolutamide (ODM-201)) in combination with standard androgen deprivation therapy (ADT) and docetaxel in patients with metastatic hormone sensitive…
- Trial name
- ARASENS (NCT02799602)
- Testing
- BAY1841788 / darolutamide (ODM-201), Standard ADT (androgen deprivation therapy), Docetaxel
- Where
- 322 sites in United States, Australia and 21 more
- Volunteers
- 1,306 people
- Sponsor
- Bayer
Diabetes Mellitus, Type 2
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec
This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to insulin icodec taken once a week in people with type 2 diabetes.
- Trial name
- COMBINE 1 (NCT05352815)
- Testing
- IcoSema, Insulin icodec
- Where
- 281 sites in United States, Australia and 20 more
- Volunteers
- 1,291 people
- Sponsor
- Novo Nordisk A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.